{"date":"2025-12-22","count":26,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-4724-2025-12-22-2159-bmh83r","company_id":"4724","company":"宣捷幹細胞","market":"興櫃","industry":"生技醫療","date":"2025-12-22","time":"21:59:09","subject":"公告本公司董事會通過之薪資報酬優於薪資報酬委員會建議","clause":"第36款","fact_date":"2025-12-22","cite_as":"公開資訊觀測站重大訊息：宣捷幹細胞（4724），2025-12-22 21:59，「公告本公司董事會通過之薪資報酬優於薪資報酬委員會建議」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6850-2025-12-22-2035-d68j7g","company_id":"6850","company":"光鼎生技","market":"興櫃","industry":"生技醫療","date":"2025-12-22","time":"20:35:23","subject":"公告本公司董事會通過現金增資子公司光鼎生物科技(江蘇)有限公司","clause":"第44款","fact_date":"2025-12-22","cite_as":"公開資訊觀測站重大訊息：光鼎生技（6850），2025-12-22 20:35，「公告本公司董事會通過現金增資子公司光鼎生物科技(江蘇)有限公司」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6850-2025-12-22-2035-s2fy2d","company_id":"6850","company":"光鼎生技","market":"興櫃","industry":"生技醫療","date":"2025-12-22","time":"20:35:01","subject":"代重要子公司光鼎生物科技(江蘇)有限公司公告董事會通過現金增資及轉增資浙江光鼎生物有限公司","clause":"第9款","fact_date":"2025-12-22","cite_as":"公開資訊觀測站重大訊息：光鼎生技（6850），2025-12-22 20:35，「代重要子公司光鼎生物科技(江蘇)有限公司公告董事會通過現金增資及轉增資浙江光鼎生物有限公司」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4120-2025-12-22-1953-1275bp4","company_id":"4120","company":"友華","market":"上櫃","industry":"生技醫療","date":"2025-12-22","time":"19:53:24","subject":"公告本公司取得仲恩生醫私募普通股","clause":"第24款","fact_date":"2025-12-22","cite_as":"公開資訊觀測站重大訊息：友華（4120），2025-12-22 19:53，「公告本公司取得仲恩生醫私募普通股」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6919-2025-12-22-1834-184xbtd","company_id":"6919","company":"康霈*","market":"上市","industry":"生技醫療","date":"2025-12-22","time":"18:34:18","subject":"公告本公司買回庫藏股期間屆滿及執行情形(更新實際買回期間)","clause":"第35款","fact_date":"2025-12-13","cite_as":"公開資訊觀測站重大訊息：康霈*（6919），2025-12-22 18:34，「公告本公司買回庫藏股期間屆滿及執行情形(更新實際買回期間)」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7729-2025-12-22-1832-1g1c704","company_id":"7729","company":"仲恩生醫","market":"興櫃","industry":"生技醫療","date":"2025-12-22","time":"18:32:09","subject":"公告董事會決議辦理114年度第一次私募普通股定價及相關事宜","clause":"第9款","fact_date":"2025-12-22","cite_as":"公開資訊觀測站重大訊息：仲恩生醫（7729），2025-12-22 18:32，「公告董事會決議辦理114年度第一次私募普通股定價及相關事宜」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4724-2025-12-22-1814-3059fs","company_id":"4724","company":"宣捷幹細胞","market":"興櫃","industry":"生技醫療","date":"2025-12-22","time":"18:14:07","subject":"公告本公司董事會決議通過修訂「113年第一次員工認股權憑證發行及認股辦法」部分條文","clause":"第9款","fact_date":"2025-12-22","cite_as":"公開資訊觀測站重大訊息：宣捷幹細胞（4724），2025-12-22 18:14，「公告本公司董事會決議通過修訂「113年第一次員工認股權憑證發行及認股辦法」部分條文」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6973-2025-12-22-1753-b1lqh9","company_id":"6973","company":"永立榮","market":"興櫃","industry":"生技醫療","date":"2025-12-22","time":"17:53:10","subject":"公告本公司董事會決議限制員工權利新股之增資基準日","clause":"第44款","fact_date":"2025-12-22","cite_as":"公開資訊觀測站重大訊息：永立榮（6973），2025-12-22 17:53，「公告本公司董事會決議限制員工權利新股之增資基準日」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6973-2025-12-22-1752-sikwj8","company_id":"6973","company":"永立榮","market":"興櫃","industry":"生技醫療","date":"2025-12-22","time":"17:52:40","subject":"公告本公司董事會追認修正114年限制員工權利新股發行辦法","clause":"第9款","fact_date":"2025-12-22","cite_as":"公開資訊觀測站重大訊息：永立榮（6973），2025-12-22 17:52，「公告本公司董事會追認修正114年限制員工權利新股發行辦法」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6467-2025-12-22-1714-5rax5d","company_id":"6467","company":"泰合","market":"興櫃","industry":"生技醫療","date":"2025-12-22","time":"17:14:44","subject":"公告本公司董事會決議員工認股權憑證轉換普通股增資基準日","clause":"第9款","fact_date":"2025-12-22","cite_as":"公開資訊觀測站重大訊息：泰合（6467），2025-12-22 17:14，「公告本公司董事會決議員工認股權憑證轉換普通股增資基準日」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6467-2025-12-22-1709-16sohr8","company_id":"6467","company":"泰合","market":"興櫃","industry":"生技醫療","date":"2025-12-22","time":"17:09:56","subject":"本公司受邀參加元大證券舉辦之線上法人說明會","clause":"第30款","fact_date":"2025-12-23","cite_as":"公開資訊觀測站重大訊息：泰合（6467），2025-12-22 17:09，「本公司受邀參加元大證券舉辦之線上法人說明會」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4128-2025-12-22-1706-ag2a8x","company_id":"4128","company":"中天","market":"上櫃","industry":"生技醫療","date":"2025-12-22","time":"17:06:19","subject":"公告本公司舉辦2025年第二次線上法說會事宜","clause":"第12款","fact_date":"2025-12-29","cite_as":"公開資訊觀測站重大訊息：中天（4128），2025-12-22 17:06，「公告本公司舉辦2025年第二次線上法說會事宜」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6620-2025-12-22-1657-1igyjof","company_id":"6620","company":"漢達","market":"上櫃","industry":"生技醫療","date":"2025-12-22","time":"16:57:45","subject":"公告本公司洽定上櫃買賣開始日並自同日起終止興櫃買賣","clause":"第28款","fact_date":"2025-12-22","cite_as":"公開資訊觀測站重大訊息：漢達（6620），2025-12-22 16:57，「公告本公司洽定上櫃買賣開始日並自同日起終止興櫃買賣」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7790-2025-12-22-1645-1cekeev","company_id":"7790","company":"思必瑞特","market":"興櫃","industry":"生技醫療","date":"2025-12-22","time":"16:45:45","subject":"本公司董事會決議通過擬取得不動產案","clause":"第44款","fact_date":"2025-12-22","cite_as":"公開資訊觀測站重大訊息：思必瑞特（7790），2025-12-22 16:45，「本公司董事會決議通過擬取得不動產案」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4747-2025-12-22-1642-128nb74","company_id":"4747","company":"強生*","market":"上櫃","industry":"生技醫療","date":"2025-12-22","time":"16:42:59","subject":"公告本公司修訂「國內第一次無擔保轉換公司債發行及轉換辦法」業經金融監督管理委員會核准","clause":"第53款","fact_date":"2025-12-22","cite_as":"公開資訊觀測站重大訊息：強生*（4747），2025-12-22 16:42，「公告本公司修訂「國內第一次無擔保轉換公司債發行及轉換辦法」業經金融監督管理委員會核准」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4104-2025-12-22-1642-1ipzoht","company_id":"4104","company":"佳醫","market":"上市","industry":"生技醫療","date":"2025-12-22","time":"16:42:58","subject":"公告本公司114年現金增資發行新股認股基準日等相關事宜","clause":"第11款","fact_date":"2025-12-22","cite_as":"公開資訊觀測站重大訊息：佳醫（4104），2025-12-22 16:42，「公告本公司114年現金增資發行新股認股基準日等相關事宜」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4120-2025-12-22-1632-p67uuk","company_id":"4120","company":"友華","market":"上櫃","industry":"生技醫療","date":"2025-12-22","time":"16:32:06","subject":"公告本公司內部稽核主管異動","clause":"第8款","fact_date":"2025-12-22","cite_as":"公開資訊觀測站重大訊息：友華（4120），2025-12-22 16:32，「公告本公司內部稽核主管異動」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6796-2025-12-22-1609-69a6aq","company_id":"6796","company":"晉弘","market":"上市","industry":"生技醫療","date":"2025-12-22","time":"16:09:07","subject":"本公司受邀參加富邦證券舉辦之法人說明會。","clause":"第12款","fact_date":"2025-12-23","cite_as":"公開資訊觀測站重大訊息：晉弘（6796），2025-12-22 16:09，「本公司受邀參加富邦證券舉辦之法人說明會。」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6794-2025-12-22-1546-rbo78s","company_id":"6794","company":"向榮生技","market":"上市","industry":"生技醫療","date":"2025-12-22","time":"15:46:36","subject":"本公司接獲CRO通知本公司開發中新藥ELIXCYTE向美國FDA申請執行治療慢性腎臟病第三期臨床試驗(IND)","clause":"第10款","fact_date":"2025-12-22","cite_as":"公開資訊觀測站重大訊息：向榮生技（6794），2025-12-22 15:46，「本公司接獲CRO通知本公司開發中新藥ELIXCYTE向美國FDA申請執行治療慢性腎臟病第三期臨床試驗(IND)」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4131-2025-12-22-1543-1p5h1m5","company_id":"4131","company":"浩泰","market":"上櫃","industry":"生技醫療","date":"2025-12-22","time":"15:43:11","subject":"公告本公司召開法人說明會相關資訊","clause":"第12款","fact_date":"2025-12-23","cite_as":"公開資訊觀測站重大訊息：浩泰（4131），2025-12-22 15:43，「公告本公司召開法人說明會相關資訊」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-1733-2025-12-22-1529-87f7k2","company_id":"1733","company":"五鼎","market":"上市","industry":"生技醫療","date":"2025-12-22","time":"15:29:33","subject":"本公司受邀參加德信證券舉辦之法人說明會","clause":"第12款","fact_date":"2025-12-24","cite_as":"公開資訊觀測站重大訊息：五鼎（1733），2025-12-22 15:29，「本公司受邀參加德信證券舉辦之法人說明會」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6491-2025-12-22-1448-r8dbg7","company_id":"6491","company":"晶碩","market":"上市","industry":"生技醫療","date":"2025-12-22","time":"14:48:59","subject":"公告董事會決議通過增資 PEGAVISION VIETNAM COMPANY LIMITED","clause":"第20款","fact_date":"2025-12-22","cite_as":"公開資訊觀測站重大訊息：晶碩（6491），2025-12-22 14:48，「公告董事會決議通過增資 PEGAVISION VIETNAM COMPANY LIMITED」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4123-2025-12-22-1440-fp3y7b","company_id":"4123","company":"晟德","market":"上櫃","industry":"生技醫療","date":"2025-12-22","time":"14:40:58","subject":"公告本公司修訂國內第六次有擔保轉換公司債及第七次無擔保轉換公司債發行及轉換辦法業經金融監督管理委員會核准","clause":"第53款","fact_date":"2025-12-22","cite_as":"公開資訊觀測站重大訊息：晟德（4123），2025-12-22 14:40，「公告本公司修訂國內第六次有擔保轉換公司債及第七次無擔保轉換公司債發行及轉換辦法業經金融監督管理委員會核准」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-3118-2025-12-22-1402-16sohr8","company_id":"3118","company":"進階","market":"上櫃","industry":"生技醫療","date":"2025-12-22","time":"14:02:50","subject":"本公司受邀參加元大證券舉辦之線上法人說明會","clause":"第12款","fact_date":"2025-12-23","cite_as":"公開資訊觀測站重大訊息：進階（3118），2025-12-22 14:02，「本公司受邀參加元大證券舉辦之線上法人說明會」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6242-2025-12-22-1358-p98gg9","company_id":"6242","company":"立康","market":"上櫃","industry":"生技醫療","date":"2025-12-22","time":"13:58:39","subject":"公告本公司受邀參加福邦證券舉辦之線上法人說明會","clause":"第12款","fact_date":"2025-12-23","cite_as":"公開資訊觀測站重大訊息：立康（6242），2025-12-22 13:58，「公告本公司受邀參加福邦證券舉辦之線上法人說明會」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7829-2025-12-22-0607-1o94e8y","company_id":"7829","company":"思捷優達-KY","market":"興櫃","industry":"生技醫療","date":"2025-12-22","time":"06:07:25","subject":"本公司代子公司思捷優達股份有限公司公告新藥YA-101獲美國食品藥物管理局 (FDA) 授予治療多重系統退化症之「快速審查認定」（Fast Track Designation）","clause":"第44款","fact_date":"2025-12-22","cite_as":"公開資訊觀測站重大訊息：思捷優達-KY（7829），2025-12-22 06:07，「本公司代子公司思捷優達股份有限公司公告新藥YA-101獲美國食品藥物管理局 (FDA) 授予治療多重系統退化症之「快速審」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}